glp-1 receptor agonists and cardiovascular outcome trials an update Kidney Outcomes Among Patients With CKD Receiving Agonists: A Systematic Review and Meta-Analysis of Randomized Cardiovascular, mortality, and kidney outcomes
Description
Two of the most talked-about medications in this area are Mounjaro and Ozempicboth injectable treatments that have demonstrated impressive results in clinical studies
00203-5/asset/a0abd16a-3eaa-4d78-990d-ba94939c04c6/main.assets/gr2_lrg.jpg)
Wyse was named to King Charles IIIs New Year Honours List for 2024
[1] [4] The timeline for GLP-1 medications to "kick in" varies depending on which therapeutic effect you're measuring and the specific medication used
A.HolmJ
The STEP trials (Semaglutide Treatment Effect in People with obesity) tested weekly semaglutide at 2.4 mg (a higher dose than for diabetes) in people with obesity (BMI 30 or 27+comorbidity)
